TOHO HOLDINGS CO., LTD. (Headquarters: Tokyo; Representative Director, CEO and CFO: Hiromi Edahiro; hereinafter “TOHO HOLDINGS”) is pleased to announce that it has established a last-mile delivery service for specialty products to patients’ homes, L1MON (hereinafter this “Service”), and will launch it as follows.

1．Background and purpose of the Service
TOHO HOLDINGS is a corporate group active in the medical, nursing and healthcare fields, engaged in pharmaceutical wholesaling, dispensing pharmacy, manufacturing and sales of pharmaceuticals, and development and provision of customer support systems under the corporate slogan “Total Commitment to Good Health”. TOHO HOLDINGS also proactively promotes initiatives for regional medical collaboration, nursing and home care.
The domestic pharmaceutical market is expected to see an expansion of specialty products and other pharmaceuticals that require strict temperature control. Through the handling of these products, the Group aims to establish a firm position as an indispensable player in the distribution of pharmaceuticals in Japan.
In addition, as digital transformation (DX) accelerates in the pharmaceutical industry with the launch of online medical care, online medication guidance, electronic prescriptions, etc., opportunities for prescribing specialty pharmaceuticals that require strict temperature control are increasing, and the last-mile delivery (delivery to patients’ homes) is required for improving patients’ drug management and access to medical care.
To address these issues, the Group has established L1MON, a patient home delivery service for specialty products. This Service utilizes the refrigerated transport under strict temperature control and delivery network provided by SAGAWA EXPRESS CO., LTD. to manage the delivery of specialty products to patients’ homes. Through the provision of L1MON, the Group will contribute to improving the quality of life (QOL) of patients who need specialty pharmaceuticals, and strive to realize higher quality drug distribution.

2．Overview of the Service
≪L1MON≫

This is a service that realizes the last-mile delivery, support treatment for patients and can be applied online. For patients who are unable to take their prescribed specialty products home on their own owing to symptoms or other reasons, we will deliver them using the refrigerated transport under strict temperature control and delivery network provided by SAGAWA EXPRESS CO., LTD.

3．Products covered
As the first drug covered by this Service, delivery of argenx Japan K.K.’s VYVDURA Combination Subcutaneous Injection to patients’ homes will begin in May 2025. VYVDURA Combination Subcutaneous Injection is indicated for the treatment of generalized myasthenia gravis (gMG) (limited to patients who do not have sufficient response to steroids or non-steroidal immunosuppressive therapies)※1 and chronic inflammatory demyelinating polyneuropathy※2. Some patients receiving the treatment have difficulty walking on their own, and carrying drugs home is a major burden.
We are confident that this Service will reduce the burden of drug take-back for patients treated with VYVDURA and provide an environment where they can focus on their treatment with peace of mind.

The Group has been promoting social implementation of this Service in anticipation of future changes in the healthcare environment, such as the spread of Myna (My Number) insurance cards, the introduction of electronic prescriptions, and the development of online medical care and online medication guidance. To ensure that this Service leads to improved access to medical care for patients, we will strive for further evolution and dissemination activities by sequentially expanding the areas covered by this Service.

※1 Myasthenia Gravis：MG＝It is a rare and chronic autoimmune disease where IgG autoantibodies disrupt communication between nerves and muscles, causing debilitating and potentially life-threatening muscle weakness.
※2 Chronic Inflammatory Demyelinating Polyneuropathy：CIDP＝It is a rare autoimmune disease of the peripheral nervous system. It can be caused by antibodies and is characterized by progressive muscle weakness and loss of sensation in the legs and arms, severely impairing the patient’s physical function.